Podcasts about neuropace

In this episode of the DeviceTalks Weekly Podcast, MassDevice Editor Chris Newmarker sits down with Wayne Paterson, CEO of Anteris Technologies, a unique start-up that's approaching the complicated and competitive TAVR market. Chris Newsmaker and Host Tom Salemi also discuss this week's Newmarker's Newsmakers including Medtronic, Boston Scientific, Johnson & Johnson MedTech, NeuroPace and the FDA. This episode was sponsored by DeviceTalks Minnesota. Register to attend the June 11 event at Minnesota.DeviceTalks.com. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

It used to be that surgery for medically refractory epilepsy was big, open and invasive, a treatment of last resort. The landscape has changed in recent decades, with more and more minimally invasive surgical approaches being developed. So what does this mean for the average patient with medically refractory epilepsy? Our guest today is Dr. Jon Willie, Associate Professor, Department of Neurological Surgery, Washington University School of Medicine in St. Louis. He speaks with Dr. Ionnis Karakis, Epileptologist and Adjunct Professor of Neurology at Emory University, about the new landscape of epilepsy surgery. Series 6, Episode 2 Featuring: Guest: Jon T. Willie, MD, PhD, FAANS, Associate Professor, Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri Interviewer: Ioannis Karakis, MD, PhD, MSc., Epileptologist and Adjunct Professor of Neurology at Emory University Disclosures: Dr. Karakis disclosed that he is a consultant for USB, GSK, Ceribell, and Epitel. Dr. Willie disclosed Consulting for Clearpoint, Inc, AiM Medical Robotics, Inc., and Fortec Medical, Inc.; Contracted Research with Abbott, Inc., Neurona, Inc., and Neuropace, Inc.; and Honoraria from Medtronic, Inc. 

Send us a textIn this third episode of the special series on Accelerating the Speed of Engineering, Joe Moak discusses key bottlenecks like changing requirements, development failures, and design challenges. He also covers strategies for managing scope changes, balancing problem-solving with team development, using tools to fail fast and cheaply, implementing checklists for success, and fostering psychological safety. Joe shares unconventional methods to expedite engineering, along with guiding principles and behaviors for teams.Main Topics:Engineering acceleration challengesManaging scope changes and team dynamicsTools for rapid, inexpensive testingChecklists for engineering successImportance of psychological safetyUnconventional methods to fast-track engineeringGoverning principles and behaviors in engineeringAbout the guest: Joe Moak is a seasoned mechanical engineer and product architect with a deep commitment to creating sustainable, user-centric products. Currently, he serves as a Senior Product Architect at Meta, where he focuses on introducing new technologies and developing product architectures. Joe is also the Founder and Chief Engineer at Maestro PD, a design engineering firm dedicated to helping clients bring high-quality hardware products to market. His extensive experience includes leadership roles at companies like Apple, Sonos, and NeuroPace, where he has driven innovation across various product lines. Links:Joe Moak - LinkedInMaestro PD WebsiteAbout Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us

  This week, we revisit our interview with Renee Ryan. Renee has 25 years of building category-creating healthcare companies. She was most recently the CEO of Cala. Prior to Cala she led the health technology investments for Johnson & Johnson Innovation (JJDC) on the West Coast and Asia Pacific for 8 years. While at J&J, she made over 15 new investments, including the Series A for Cala Health. Previously, she was a healthcare investment banker at RW Baird, Jefferies and Goldman Sachs.  Renee currently sits on the boards of Cala, Neuropace and RefleXion Medical. 

In this episode of Medsider Radio, we sat down with Brett Wingeier, co-founder and CTO of Magnus Medical, a privately held medical device company whose FDA-cleared SAINT™ Neuromodulation System aims to revolutionize mental health care. Brett is a prominent figure in neuromodulation, leveraging his expertise in medicine, biology, and engineering to advance the arena within medtech. He was part of the pioneering team at NeuroPace and also co-founded Halo Neuroscience. In this interview, Brett shares valuable insights into understanding the system you're working with, balancing consumer and provider perspectives, and ensuring cost-effectiveness for successful reimbursement.Before we jump into the conversation, I wanted to mention a few things:If you're into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You'll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a MedTech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you're interested, go to medsider.com/subscribe to learn more.

Microbot Medical's completion of a pre-clinical study for its endovascular surgical robot signifies a significant milestone for the company. Fast Five hosts Danielle Kirsh and Sean Whooley explain what the surgical robot does and what the outcome of the pre-clinical study was. The FDA clearance of Boston Scientific's Embold Soft & Packing coils demonstrates the company's commitment to expanding its portfolio of innovative solutions for embolization procedures. Hear about what the coils are designed for and how it streamlines hospital workflows on today's episode. Integra Lifesciences' completion of enrollment in the DuraSorb monofilament mesh IDE study is a significant step toward gathering valuable clinical data for this product. Whooley details what the study will evaluate and how optimistic are executives at the company. Federal prosecutors claim a former DePuy Synthes sales representative defrauded an undisclosed Boston area hospital, with hundreds of thousands of dollars worth of spine products involved. Kirsh and Whooley share what the sales representative is accused of, how it allegedly benefitted the sales rep and DePuy Synthes' response.  The resignation of NeuroPace's CEO and the appointment of a former Integer executive as his successor mark a significant leadership change within the company. Whooley and Kirsh discuss the details behind the resignation and who is taking over the corner office. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.

In this episode of DeviceTalks Weekly we'll talk with Mike Favet, CEO of NeuroPace, about how the company's RNS technology is helping to transform the lives of patients with drug-resistant epilepsy. NeuroPace, one of the pioneers in neurostimulation, has the only FDA-approved neurostim treatment for epilepsy. Favet took over as CEO four years ago from the founding CEO so we discuss his background, the changes he made at the company, and how NeuroPace is building a market for a medical device to treat a disease that typically can be managed only by pharmaceuticals. Mike Favet will be a panelist on a keynote panel about building a neuromodulation market at DeviceTalks West on Oct. 18-19 at the Santa Clara Convention Center. Co-hosts Tom Salemi and Chris Newmarker introduce a new formula for the Newmarker's Newsmaker. Companies mentioned including Philips, Biotronik, Medtronic, Johnson & Johnson, GE Healthcare, Depuy Synthes, BD, and many others. Thanks for listening to the DeviceTalks Podcast Network. Subscribe to this network on any major podcast app.

One of the opportunities in healthcare today is how information is exchanged to help address and solve complex conditions, and at the core of this opportunity is the foundation of medical education and those that continue to share perspectives and expertise in specific areas of practice. This episode focuses on neurology and how the science will continue to help evolve the healthcare industry and the emerging technologies that will pave the way to the future. The topic is timely given the many recent advances in technology and considering how this trend will continue to uncover meaning and insights into “the black box of the brain”. This episode's guest is Dr. Michael Kentris, Neurologist, Podcaster, and Medical Education Advocate. During his work, Dr. Kentris has been involved in a variety of activities, most recently as a Practicing Neurologist, Narrator for the American Academy of Neurology, as well as Creator of “The Neurotransmitters: A Clinical Neurology Podcast”. Other topics range from the future of remote learning and the democratization of education to the ethical and cyber-security implications of brain-computing-interfaces to the importance of decreasing cost on health-tech to reach more people. For more details visit TechLink Health on the web or connect with Dr. Kentris via Linktree or within the TechLink Health app. This episode was hosted by David Sanchez, RN, Medical SEO Consultant and Dr. Sarah Samaan. The episode is packed with valuable insights and points to several references:

In this episode featuring Dr. Selim R. Benbadis, listen in on the causes of epilepsy misdiagnosis, review conditions most commonly misdiagnosed as epilepsy, and discuss diagnosis management of psychogenic (functional) seizures.  Accreditations PHYSICIANS ACCME USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. USF Health designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. Florida Board of Medicine USF Health is an approved provider of continuing education for physicians through the Florida Board of Medicine.  This activity has been reviewed and approved for up to 0.25 continuing education credits.  Target Audience: All physicians Release Date: 5/23/2022 Expiration Date: 5/23/2023 Relevant Financial Relationships All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships. Selim Benbadis, MD: Advisory Board or Panel for Bioserenity, Ceribell, Eisai, Greenwich, LivaNova, Neurelis, Neuropace, SK life science, Sunovion, Zogenix, National Medical Director for RSC Diagnostic Services (EEG), and Florida Medical Director for Stratus (EEG); Consultant for Bioserenity, Ceribell, Eisai, Greenwich, LivaNova, Neurelis, Neuropace, SK life science, Sunovion, and Zogenix; Grants/ Research Support for Cerebral Therapeutics, Cerevel, Neuropace, Greenwich, SK Life Science, Takeda, Xenon; Speaker's Bureau for Aquestive, Bioserenity, Eisai, Greenwich, LivaNova, Neurelis, SK life science, Stratus, Sunovion, and Zogenix. Claim Credit HERE. Visit cme.tgh.org for other CME opportunities, including live webinars, on-demand videos and local events offered to you by Tampa General Hospital.

This week we interview Renee Ryan, CEO of Cala. Renee has 25 years of building category-creating healthcare companies. Before joining Cala as CEO in August 2019, she led Johnson & Johnson Innovation (JJDC) on the West Coast and the Asia Pacific for eight years. While at J&J, she made over 15 new investments, including the Series A for Cala Health. Previously, she was a healthcare investment banker at RW Baird, Jefferies, and Goldman Sachs.  Renee currently sits on the boards of Cala, Neuropace, and RefleXion Medical. 

Welcome back to the Season 2 premiere of Neurotech Pub!In this episode, host and Paradromics CEO Matt Angle sits down with fellow Founder/CEOs Carolina Aguilar, Brian Pepin, and Kunal Ghosh to talk shop about building cutting edge neurotech companies from the ground up. We dive deep into business strategies, the neurotech fundraising landscape, emerging therapeutics, and more. We also provide an insider's view of the intersections of data, pharma, and med devices that are shaping the future of healthcare. Pour yourself a cold one and settle in! Check out full video with transcript here: Check out video and a full episode transcript here. 00:00 | Updates & News >> INBRAIN Neuroelectronics raised a $17M Series A >> Rune Labs raised a $22.8 Million Series A >> Inscopix Launched Cloud-Based Platform for Data Management and Analysis2:15 | Meet the panel and pick up a book1:54 | Jester King Brewery  2:25 | Rune Labs  2:50 | Neurostimulator for deep brain stimulation therapy  3:23 | INBRAIN Neuroelectronics  4:11 | Inscopix  5:24 | Ursula K. Le Guin's 'The Dispossessed'  6:19 | Yuval Noah Harari's 'Sapiens: A Brief History of Humankind'  6:32 | Daniel G. Miller's 'The Tree of Knowledge'  6:40 | Jiddu Krishnamurti's 'The Book of Life'  7:34 | Barack Obama's 'A Promised Land,' ‘Dreams from my Father,' & ‘The Audacity of Hope'  7:56 | Karl Popper's 'The Open Society and Its Enemies'9:25 | Venture Capital in Neurotech34:44 | Business Strategy in Neurotech40:32 | Tom Oxley, CEO, Synchron  43:58 | Dr. Thomas Insel  44:06 | Mindstrong Mental Health Care  44:35 | Aduhelm controversy  52:25 | Galvani Bio  59:39 | Percept Neurostimulator  1:00:32 | Neuromodulation and the future of treating brain disease  1:07:21 | Software as a Medical Device FDA Guidance1:09:12 | State of Animal Model Systems1:14:28 | α-Synuclein in Parkinson's Disease  1:18:01 | Alto Neuroscience  1:18:36 | Flatiron Foundation  1:18:45 | Gaurdent Health  1:19:03 | Melanoma Trends & Rates1:21:41 | The Pharma-Data-Device Ecosystem 1:21:42 | Frank Fischer, Chairman of Neuropace  1:22:28 | Neurotech Pub Season 1, Episode 9  1:26:35 | Roche acquisition of Flatiron Health & merger with Foundation Medicine   1:27:12 | Companion Diagnostics  1:28:29 | Adhulem and PET imaging  1:29:09 | Resignations at the FDA over Alzheimer's Drug  1:29:32 | Derek Lowe's take on the Aducanumab Approval, FDA Committee Votes, Halting the Aducanumab Trials, & The FDA Advisory Committee Briefing Document on Aducanumab  1:31:39 | Donanemab receives breakthrough therapy designation in 2021  1:36:58 | Mapping the Frontal-Vagal Pathway  1:37:09 | The Human Connectome Project  1:40:07 | Teal Organizations and Holacracy  1:41:18 | Society for Neuroscience  1:44:37 | Affymetrix (Thermo Fisher Scientific)  1:44:39 | IlluminaWant more?Follow Paradromics & Neurotech Pub on Twitter  Follow Matt, Brian, Carolina, & Kunal on Twitter

In this episode of Medtech Matters, a podcast focused on the medical device manufacturing industry and the factors impacting it, we speak with Mike Favet, CEO of NeuroPace. He offers insights into how his technology helps those suffering with epilepsy. In addition, he provides an explanation of the firm's nSight Platform. Finally, he talks about the partnership with another organization focused on epilepsy and how it integrates with his firm's technologies. Specifically, the following questions are addressed.Can you please explain what the focus of your company NeuroPace is?What is the nSight Platform and how does it lead to a better treatment protocol for patients with epilepsy?Why have you partnered with Seizure Tracker?With the three of these systems combined and working together, what is the impact to those with epilepsy?What's next for NeuroPace? What are the next steps?Listen to this episode and see what you think of these epilepsy solutions. If you'd like to share thoughts, ask questions, or suggest a future participant for Medtech Matters, please reach out to me at sfenske@rodmanmedia.com.

In this episode, Liz interviews Emily Mirro and Chad Hamilton from NeuroPace on the qualities of a great med device facilitator. Chad brings his expertise with sales field rep training, while Emily brings her experience in clinical education.

Our guest today is Michael Favet. His current work at NeuroPace, where he serves as President and CEO, focuses on their new and innovative technology tracking brain waves to predict epileptic attacks and prevent them by electrically stimulating the brain. Although Michael was actually an engineer straight out of college, he has had a long and storied 30-year career in the medical device field. He has served as CEO of multiple different companies and spent three years as a venture investor. This gives him an interesting perspective on his work at NeuroPace as well as his career as a whole, in understanding both the business and the medical side. In this episode, Michael explains how he went from an engineer from the University of Illinois to a CEO of a revolutionary medical device company in the Bay Area. Do you have any thoughts? Please email us at hello@rosenmaninstitute.org. We post new episodes every Monday. “The Health Technology Podcast” is produced by Herminio Neto, hosted by Christine Winoto, and engineered by Andrew John Rojek.

Welcome to the Season 1 finale of Neurotech Pub! In this episode, host and Paradromics CEO, Matt Angle, speaks with fellow Neurotech CEOs, Konstantinos Alataris, Frank Fischer, and Marcus Gerhardt. "We cover a lot in this discussion, but one of the big themes is how challenging it can be to raise money, to build neuro devices. This episode was originally recorded last winter, and it was instantly one of my favorite episodes. So like a fine wine, I laid it down until the time was right to share it with friends.Since the episode was recorded, Nesos, Paradromics, and BlackRock all had major funding announcements. Nesos and BlackRock underwent rebranding campaigns, and NeuroPace went public on Nasdaq. This podcast was recorded during a bleak winter, but our optimism proved prescient. The podcast aged well, and now the field is the strongest, best funded, and most exciting that it's ever been. I know you'll enjoy the discussion."- Matt Angle, CEO, ParadromicsCheck out full video with transcript here: https://www.paradromics.com/podcast/neurotech-pub-episode-9-building-and-funding-neurotech-companies 01:08 | Meeting Heros08:02 | Company Origins: NeuroPace, Blackrock Neuro, and Nēsos25:28 | Now vs Then, a Decade of Neurotech Entrepreneurship1:04:50 | Investor Backing in Neurotech1:20:44 | BCI Future Is UnderwayWant more? Follow Paradromics & Neurotech Pub on Twitter  Follow Matt A, and Blackrock Neurotech on Twitter

This week we'll focus on investor insights. First, we'll talk with Danielle Antalffy, managing director at SVB Leerink. Antalffy covers most of the major medtechs but we'll focus on a new report she issues on sugaring home-based dialysis business. What does this mean for Outset specifically? More broadly, do other medtechs need to build out their at-home/connectivity function? Also, what does NeuroPace's success mean for other medtech companies. In a follow up to our interview with Dr. James Min, CEO of Cleerly Health, we talk with two venture investors in the early heart attack risk detection company. Justin Klein, MD, of Vensana Capital walks us through the steps he took before leading the company's recent $43 million Series B round. Tripp Peake of LRV Health explains why the company interests his venture firm's limited partner base. This is an opportunity for entrepreneurs to better understand the venture capital due diligence process. Chris Newmarker, executive editor of life sciences, delivers his Newmarker's Newsmakers brings top news from Conformis, Stryker, Siemens Healthineers, Abbott, Medtronic and Levita Magnetics. LIKE! FOLLOW! SUBSCRIBE! We're on most major podcast channels.

In this podcast, iRhythm CEO Mike Coyle discusses his decision to join the digital health leader in January. Coyle’s had to hit the ground running as iRhythm manages some challenging decisions from regional Medicare payors but he also sees great opportunity for the company’s ZIO platform across the healthcare spectrum. In this conversation, Coyle discusses • How he came to join the Medtech industry. • The potential for its ZIO cardiac monitoring technology • How the company is dealing with a disappointing reimbursement • How the company will pursue the large asymptomatic market • What’s expected to come from the company’s partnership with Verily We also introduce the newest member of our DeviceTalks Podcast family. Catch an excerpt of the first episode in this week’s podcast. Subscribe to hear future episodes. Caffeine-fueled Chris Newmarker, executive editor of life sciences at Mass Device, takes a break from earnings week to roll out a powerful #newmarkersjnewmakers bringing news from Zimmer Biomet, Stryker, Emergent Biosolutions, Intuitive Surgical, Medtronic and NeuroPace. Subscribe on all major podcast players.

The president and CEO of Neuropace Inc. (NPCE), Mike Favet, says that the commercial-stage medical device company created a RNS System for drug-resistant epilepsy. The stock began publicly trading today with shares opening for trade at $23.25 per share.

In this week’s podcast, Medtech Insight managing editor Reed Miller discusses Augmedics’ and NeuroPace’s financing deals, and UK-based reporter Barnaby Pickering offers some insights from Octopus Ventures, a venture capital fund based in London. Listen to the podcast via the player below: Medtech Insight articles addressing topics discussed in this episode: Investor Eye: Octopus Ventures Tackles Tough, Taboo Problems In Health Care NeuroPace Seeks $75M In IPO Augmedics Raises $36M To Support Stereotactic Surgical Navigation For more information on Medtech Insight and to start a free trial, click here: http://bit.ly/2w7LnlR

Jordan interviews Rob Moxon, a Regional Manager at NeuroPace, developers of the award-winning RNS® System for treatment of neurological disorders with responsive stimulation. They discuss the intense training that comes with breaking into the industry, how Rob evolved his career from a clinical specialist to a sales director, and the advice he offers to those looking to make a similar transition.

Frank Fischer, Chairman of the Board, Neuropace Frank Fischer has more than 40 years of senior management experience in the medical device industry. He co-founded NeuroPace in Dec 1997, led the company as its President and Chief Executive Officer from January 2000 thru July 2019, served on its Board of Directors since inception and is currently Chairman of the Board. Prior to joining NeuroPace, Mr. Fischer was President and Chief Executive Officer of Heartport, Inc., a cardiac surgery company, from May 1998 until September 1999 and served on Heartport's Board of Directors. Previously, Mr. Fischer was President and Chief Executive Officer and a director of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators, from July 1987 until the sale of the company to St. Jude Medical, Inc. in 1997. Before joining Ventritex, he held various management positions at Cordis Corporation from 1977 to 1987 in the cardiac and neurosurgical device areas, serving most recently as President of the Implantable Products Division. Currently he is a member of the Board of Directors of Nevro, Inc., the Board of Trustees of both Rensselaer Polytechnic Institute and Babson College as well as the Board of Directors of the Epilepsy Foundation of America. Mr. Fischer holds B.S.M.E. and M.S. in Management degrees from Rensselaer Polytechnic Institute.

Greetings, SuperFriends! Today we are joined by Dr. Brett Wingeier, currently CTO and co-founder of Halo Neuroscience. Dr. Brett himself is an engineer and neuroscientist with twenty years of experience creating science-based products to unlock human potential and treat disease. He is also the co-creator of Halo Sport, the world's first convenient, wearable neurostimulator for athletic training. Prior to Halo, Dr. Wingeier was a principal engineer and clinical scientist at NeuroPace, bringing to market the first fully-implantable responsive neurostimulator for epilepsy. Really cool stuff! Now, I wanted to have Dr. Wingeier on the show because many of you have reached out to me and asked about the Halo Sport, this device that you supposedly put on your head and it makes you learn motor skills faster. So, I reached out to the company, told them that my audience is asking about their product, and requested that I talk to someone from their team. They said "absolutely", they were kind enough to send me a unit, and they told me that I could ask all the questions I want to their CTO and co-founder. And that's exactly what I did. So, for those of you that want to know whether this works, yes, it does. If you want to learn how it works, you will learn more about Dr. Wingeier himself in the episode. I really enjoyed the episode because it gave me the opportunity to go into a part of accelerated learning that I normally don't get to go so deep on, and that I normally feel is a hole in my knowledge. That is, can we accelerate the learning of physical motor skills, and can we make our brain connect to our body in faster and more efficient ways? Spoiler alert, the answer is yes, and in this episode, you will learn how. We also go a bit deeper into the crazy ways that you can use electronics and technology to change our brains. I really enjoyed this episode, and I'm sure you will do so as well! -Jonathan Levi

In this episode, Mike Favet, the new CEO of NeuroPace, shares his personal story into Medtech and reveals his plans for one of Medtech’s pioneers, NeuroPace. What convinced him to become CEO? What changes will he make at NeuroPace?

In this interview, Frank Fischer and Martha Morrell, MD, recount the long history of NeuroPace, one of Medtech’s neurostimulation pioneers.

In this episode of the Deep Change Podcast, we dive into the world of neuropriming, hyperplasticity, and how to increase your learning speed by up to 50%. Using transcranial direct current stimulation (i.e., electricity), Halo Neuroscience founder Dr. Daniel Chao explores the possibility of turning back time and getting your adult brain to learn as fast as kids' brains learn. You don't want to miss this episode! Check out Halo Neuroscience here: https://haloneuro.com (for $75 off, use Discount Code: BRAINBYDESIGN) Subscribe to my podcast here: https://itunes.apple.com/us/podcast/deep-change-podcast/id1453064765?mt=2&uo=4 -------------- Dr. Daniel Chao is a neuroscientist and entrepreneur who specializes in technology that improves brain performance. He’s the Co-Founder of Halo Neuroscience, a venture-backed human performance company based in the Bay Area. The company's first product, Halo Sport, is the world's first neurostimulation system built specifically to accelerate the development of muscle memory from training. Prior to founding Halo, Dr. Chao was the head of business development at NeuroPace, where he helped create the world's first closed-loop neurostimulation device for the treatment of epilepsy. He received his M.D. and M.S. in neuroscience from Stanford University. --------------------- Affiliate Disclosure: If you purchase something from Halo Neuroscience and use the above discount code, I will receive a small amount of that sale, which helps me keep the lights on and allows me to keep making good content.

This is the first episode of a new monthly series of the neurotech industry round-up. If you don't have time to scan the headlines every day, listen to this podcast to get a summary of the news over that last month. Joining Ladan is Jen French and Jim Cavuoto from Neurotech Reports to review what is drawing attention in the neurotechnology industry. Some of the headlines focused on regulatory approvals of devices in the areas of heart failure, sleep apnea, migraine, and Parkinson's disease, as well as the passing of the reign of NeuroPace from Frank Fischer to Michael Favet. We also highlighted the market of obesity and the variety of neurotechnology approaches for the treatment of this condition.    3 Takeaways: Several neurotech devices gain regulatory approval of the last month as the neurotech competition heats up. The research and commercialization of devices for the treatment of obesity explands with an array of approaches. Recent development from the company Humm who is marketing a non-invasive tACS device and research from the University of Houston in the area of PTSD.

On this episode of Living Beyond 120, Mark and Dr. Gladden invite Daniel Chao on the show to talk about the benefits of using Halo Sport, a brain muscle stimulator that can help you develop muscle memory faster. Chao describes how the device works and improves neuroplasticity.   They explore the various ways this can benefit your brain and body. Dr. Gladden reports the many ways the Halo Sport has helped him personally during and after using it. They discuss how Halo Sport can help in the short term, as well as its ability to improve cognitive function as people age. About the guest: Daniel Chao is a neurotech entrepreneur, specializing in devices that improve brain performance. Most recently, Daniel co-founded Halo Neuroscience, a human performance company based in San Francisco, and was the company's CEO until March 2019. While CEO, Daniel lead the launch of the world's first consumer neurostimulation system, Halo Sport. Prior to Halo, Daniel was the head of business development at NeuroPace, where he helped raise $250M in capital to develop the world's first closed-loop neuromodulation device, winning FDA approval for the treatment of epilepsy in a unanimous 13-0 vote. Before NeuroPace, Daniel was a consultant at McKinsey & Company and he received his M.D. and M.S. in neuroscience from Stanford University.   Follow Daniel and his company on Twitter

In this episode we discuss cutting edge brain hacks that sound like they are straight out of science fiction. Is it possible to use technology to rapidly change the structure of your brain? How does your brain actually learn? What is neuroplasticity and why is it so important? What are the key things you can do in your life to improve your brain health, memory and performance? We discuss all of this, along with a truly innovative technology that may be the key to unlocking super performance and massively accelerating your learning with our guest Dr. Daniel Chao. Dr. Daniel Chao is a neurotech entrepreneur, specializing in devices that improve brain performance. He is the co-founder and CEO of Halo Neuroscience. The company’s first product, Halo Sport, is the first neurostimulation system built specifically for athletes. Before Halo, Dr. Chao was the head of business development at NeuroPace, and a consultant at McKinsey & Company.Your brain is a living computer chip that can create new circuits on demandYour brain is “plastic” The Nobel prize in the year 2000 went to the scientists who discovered neuroplasticity and the mechanisms behind itNeuroplasticity is the process by which the brain learnsWhat actually happens in the brain when you are learning a new skill?What happens to the brain and your neural connections when you learn a new skill?Focused, repetitive, deliberate practice starts to build thicker and thicker and faster and faster neural connections Repetition is the foundation of practice - you’re literally building physical connections in your brain that get stronger and stronger, the more you repeat that practice The first time you learn something it’s like hacking a path through the jungle with a machete, then it’s like hiking through tough brush, then it’s a dirt road, then it becomes a paved road, then ultimately a highway and a superhighway “Myleanation”- the cabling inside the brain The brain is a plastic organ and it adapts to your needs Repeated practice, learning, and thoughts literally change the physical structure of your brain The brain is literally built on the principle of “use it or lose it” - if you aren’t using your brain, those parts atrophy and shrink What are some strategies we can implement to optimize our brain and improve our brain health?Sleep is one of the most important and obvious strategies for optimizing and improving brain health. Your day is “unequal”- you have better executive function in the first part of the day. Prioritize the most difficult and most important work in the early part of the day because you will be at a cognitive peak. How can we take advantage of emerging brain science to “hack” the brain or “hack” learning? What if you put electrodes into your brain to stimulate learning and memory?Starting in our late teens, our ability to learn stats to decline - can we use cutting edge science to reverse that?If you use electrical stimulation on your brain - it opens up about an hour of “hyper plasticity”- a super learning window Slapping a “motor cortex neurostimulator” onto your brain - can be for any physical activity, playing violin, shooting a gun, playing video games, performing surgery etc What happens to the additional “lift” in learning you get from neurostimulation? How “durable” is that learning?The safety data for neurostimulation is incredibly robust- over 250,000 neurostimulation sessions its incredibly safe, there are over 4000 scientific articles about the safety of neurostimulation Homework: Sleep, exercise is GREAT for brain health. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Daniel Chao is a neuroscientist and entrepreneur who specializes in technology that improves brain performance. He is the Co-Founder and CEO of Halo Neuroscience, a venture-backed human performance company based in San Francisco. The company's first product, Halo Sport, is the world's first neurostimulation system built specifically to accelerate the development of muscle memory from training. Prior to founding Halo, Dr. Chao was the head of business development at NeuroPace, where he helped create the world's first closed-loop neurostimulation device for the treatment of epilepsy. He received his M.D. and M.S. in neuroscience from Stanford University. Dan stops by to reminisce about his time at Stanford, where Halo is now, and what new Halo products are in the works.Connect with team Halo:Website | https://www.haloneuro.com/Blog | https://blog.haloneuro.com/Instagram | https://www.instagram.com/haloneuroscience/Facebook | https://www.facebook.com/halo.neuroscienceTwitter | https://twitter.com/haloneuro?lang=enShow Notes:Neuropace | https://bit.ly/2QmmvxdRadiolab 9 volt nirvana | https://bit.ly/2LVdSJHConnect with Kyle Kingsbury on:Twitter | https://bit.ly/2DrhtKnInstagram | https://bit.ly/2DxeDrkGet 10% off at Onnit by going to https://www.onnit.com/podcast/Connect with Onnit on:Twitter | https://twitter.com/Onnit      Instagram | https://bit.ly/2NUE7DWSubscribe to Human Optimization Hour Itunes | https://apple.co/2P0GEJuStitcher | https://bit.ly/2DzUSypSpotify | https://spoti.fi/2ybfVTY

For episode 117 we're learning from the best of the best companies that intersect at the crossroads for the future of health and wellness technology.   This is a topic we’ve explored over the past 100+ shows on Wellness Force Radio, but for 117 we’re going the deepest we’ve ever gone to address the most important question around this type of technology, much more important than just technology itself: How exactly can health and wellness technology including apps, wearables, smart garments, and smart devices truly help us get more physically and emotionally intelligent so we can live life well?    This is a big question that will affect not just national, but global health, so this deserves some big answers. That’s why today on the podcast we're bringing you not just one, but three doctors and industry experts in the fields of smart garments, with Dr. Tim Brown, founder of IntelliSkin, in brain neuroplasticity and neuropriming, with Dr. Daniel Chao, Co-Founder of Halo Neuroscience, and how the future of doctors will care for patients at home is actually here right now, with Dr. Renee Dua, Co-Founder of Heal.   JOIN THE FACEBOOK GROUP | REVIEW THIS PODCAST   If you’re a tech-focused wellness enthusiast, or if you’re brand new to exploring how technology can help you in your wellness journey, you're equally going to love this episode...   Many of the concepts we’re discussing today are brand-new to the show, and we've handpicked these guests out of all the noise online to get clarity on what brands in wellness technology we can use today that will help secure better personal wellness for our future.   Listen To Episode 117 As Our Special Guests Uncover Dr. Tim Brown – IntelliSkin Using smart garments to retrain the body's awareness of its position in space Upper Cross Syndrome: “Death By Chair” How posture affects immunity, hormones, breath, and overall health and what we can do about it The 3 areas we all must keep flexible and why: ankle dorsiflexion, hip mobility, thoracic spine mobilization Dr. Daniel Chao – Halo Neuroscience Why professional sports teams are using Halo Sport with Halo Neuroscience What is “neuropriming”  (tDCS, transcranial direct current stimulation) and what does it do for human performance How a 20 minute application in the electric field will induce temporary state of “hyperlearning” Breaking the 10,000 hour mastery rule: With tDCS, new skill acquisition may be possible to learn in half the time Dr. Renee Dua – Heal App Why emergency rooms in the United States are beyond capacity and how Heal is changing the current paradigm of patient care What is the future of medical doctors delivering care on-call and insurance reimbursement How mHealth and health and wellness technology like Heal are disrupting the medical world forever What are the patient benefits of having doctors on call through a mobile app vs. current facility-only care models Resources From Dr. Tim Brown IntelliSkin Discount: Use code JoshTrent15 for a 15% discount up to a week from the broadcast. IntelliSkin Technology “Text Neck” “Computer Back” Davis's Law Upper Cross Syndrome Dr. Vladimir Janda Major League Sports + Athletes Using IntelliSkin James Andrews, Orthopedic Surgeon Alvaro Romano: Ginastica Natural 5 Tibetan Rights Dr. Tim Brown: 5 Tibetan Rights IntelliSkin on facebook IntelliSkin on Twitter IntelliSkin on the web IntelliSkin on Instagram Resources From Dr. Daniel Chao Halo Sport Discount: Get $125.00 off Halo Sport by using code WELLNESSFORCE125 at checkout The $7 billion industry of selling implantable neurostimulators to treat disease Hyper plasticity + hyperlearning Neuropriming:  tDCS, transcranial direct current stimulation Priming your brain for a training session “Feeding the brain” quality movements: replicating ideal movements better for each training session NBA + NFL teams using Halo Sport Long Term Potentiation Halo Neuroscience Announces partnerships with San Francisco Giants Fitness + Technology Podcast The future of Halo Sport: Human Performance company Halo Neuroscience on facebook Halo Neuroscience on Twitter Halo Neuroscience on the web Halo Neuroscience on Instagram Resources From Dr. Renee Dua Heal: This App Will Send a Doctor to Your House for $99 Why 71% of emergency room visits are unnecessary Perfecting the “house call” Heal is the Uber of doctor visits  Licensed, background-checked pediatricians for kids, general practice and internal medicine doctors for adults and family practice doctors for the whole family. Benefits of Using Heal: Case study – Stylishly Social Needless medical tests not only cost over $200 billion, they can do harm Patient-Generated Health Data is Valuable Personalization Tool Heal App: Expanding Nationwide Heal App on iOS Heal App on Android Heal on facebook Heal on Twitter Heal on the web Heal on Instagram About Our Featured Guests Dr. Tim Brown, Founder, IntelliSkin IntelliSkin inventor, Dr. Tim Brown, grew to understand his future creation while working as the medical director on the ASP surf and AVP volleyball tours during the 1980’s. As an early innovator in functional taping, he developed a hybrid kinesiology technique known as SPRT (Specific Proprioceptive Response Taping). Used on everyone from Olympians to NFL players, the technique quickly became a staple in the athletic world as it allowed injured athletes to compete despite their injuries.   Dr. Brown’s instinctive techniques got athletes asking for taping remedies so often, that he needed something that could do the job when he wasn’t there. Many late nights of trial and error using remnants of old wetsuits and rash guards, he devised a wearable technology that mimicked his taping technique. Dr. Brown’s goal was to take what he had learned in designing and come up with a comfortable, Smart Compression shirt that would clinically improve posture and spinal alignment for everyone, whether you’re an elite athlete or a weekend warrior. Dr. Brown’s ultimate goal is to help everybody to look better, feel better and perform better. He continues to pursue that goal every day.   Dr. Daniel Chao, Co-Founder, Halo Neuroscience   Daniel Chao is a neurotech entrepreneur, specializing in devices that improve brain performance. Currently, Dan is co-founder and CEO of Halo Neuroscience, a venture-backed human performance company based in San Francisco. The company's first product, Halo Sport, is the world's first neurostimulation system built specifically for athletes.   Prior to Halo, Dan was the head of business development at NeuroPace, where he helped raise $250M in capital to develop the world's first closed-loop neuromodulation device, winning FDA approval for the treatment of epilepsy in a unanimous 13-0 vote. Before NeuroPace, Dan was a consultant at McKinsey & Company in the New York office, and he received his M.D. and M.S. in neuroscience from Stanford University.   Renee Dua, Co-Founder, Heal   Dr. Renee Dua is Founder and Chief Medical Officer of Heal – an LA-based start-up providing on-demand house call medicine. Dr. Dua is a Board certified nephrologist and internal medicine doctor who has served as Chief of Medicine at Valley Presbyterian and Simi Valley Hospital. After building a thriving private practice and also teaching medicine at UCLA, Dr. Dua embarked on her greatest adventure, being mom to her first child, a now 15-month old little boy.   It was her son that led her to create Heal, because she knew moms and dads everywhere needed an easier way to see a doctor. As a mom-doctor doing her first start-up, Dr. Dua often jokes she’s a doctor-mom-preneur. Dr. Dua resides in the Pacific Palisades with her husband and son.   GET MORE WELLNESS IN YOUR LIFE Join the WFR Community on facebook Send Josh Trent a personal message Tweet me on Twitter: Send us a fun tweet (or a what's up) Comment on the Facebook page Sign up to get an email alert whenever we release a new episode SUPPORT THIS PODCAST Leave a 5 star review on iTunes Share this episode with someone you care about Contact Wellness Force Radio for podcast sponsorship and partnership opportunities RATE & REVIEW WELLNESS FORCE Aloha! Josh here. Listen, I deeply value your thoughts, now let your voice be heard. I live to serve the Wellness Force even better based on your words, feedback, and requests. (including how these episodes can allow you to break bad habits)   ASK A LIVE QUESTION FOR THE NEXT EPISODE Click here to leave a voicemail directly to Josh Trent to be read live on the air.  YOU MAY ALSO LIKE THESE EPISODES Food Freedom Forever With Melissa Hartwig Nir Eyal:Breaking Bad Habits, Technology Addiction, & Emotional Triggers Healthy, Happy & Harder To Kill w/ Steph Gaudreau of Stupid Easy Paleo Beyond Meditation: How To Get A Better Brain With Ariel Garten Living A Healthy Lifestyle In A Modern World With Dan Pardi Creating A Life Worth Living With Michael Strasner GET MORE WELLNESS IN YOUR LIFE Join the Wellness Force Newsletter: www.wellnessforce.com/news Don't miss next week's show: Subscribe and stay updated Did you like this show? Rate and review Wellness Force on iTunes You read all the way to the bottom? That's what I call love! Write to me and let me know what you'd like to have to get more wellness in your life.

Our guest for today’s episode is Dr. Daniel Chao, CEO at Halo Neuroscience.  Daniel Chao is a medtech entrepreneur, specializing devices that improve brain performance, and currently is the co-founder and CEO of Halo Neuroscience based in San Francisco developing neuroscience-based technology that accelerates performance gains for elite athletes. Today’s podcast is all about the brain, learning, skill acquisition and achieving better performance.  Topics include neuroplasticity, neural drive, chemical vs. electrical stimulation to the brain, and more. As we move through decades of training and sports science, it’s interesting to see what becomes common in popular culture.  Pre-workouts have become a cultural, and even meme phenomenon, but are they really helping drive better performance in competition?  Are the benefits outweighed by the cost, and is there a better way to stimulate the brain for optimal learning? Dr. Chao goes in depth on skill learning, and the future of enhancing the brain for performance gains. Today’s episode is brought to you by SimpliFaster, supplier of high-end athletic development tools, such as the Freelap timing system, kBox, Sprint 1080, and more. Key Points: Chao’s background in the neuroscience field Neuroplasticity and its role in learning Neural drive and EMG in performance Endurance performance and the brain Physical learning and classroom learning similarities and differences The importance of sleep, neurotransmitters, and learning The effect of chemicals on the brain and learning Quotes “Drugs work well for the rest of the body, it’s arguably the miracle of modern medicine, but when you think about drugs and when they are applied to the brain, the wheels kind of fall off” “If you put people who are moving into an FRMI scanner, or even thinking about moving, the motor cortex is lighting up like a Christmas Tree" “Neural drive is the raw electrical output that comes out of the brain and produces a muscle contraction.  You can teach your brain to generate more neural drive to fire more muscle fibers more robustly” “For learning a motor skill, that’s your motor cortex, your cerebellum, and deeper parts of your brain like the thalamus.  For learning facts in say a chemistry classroom, for example, that’s a part of your brain that’s more frontal” “We’ve known this for a long time, and the science continually reinforces that we need to sleep, and we still don’t do it.  We try to shortcut sleep constantly” “There’s the type of practice where you’re just mindlessly going through the motions… that is not going to work as well than thoughtful, really deliberate, quality practice.  From a physical standpoint, this is really important, because reps are precious” “Practice is done through repetition, you need to be engaged in that repetition, you need feedback in that repetition” “Dynamic range is the distance between where you are at today and your genetic potential” About Dr. Daniel Chao Daniel Chao is a medtech entrepreneur, specializing devices that improve brain performance. Currently, Dr. Chao is co-founder and CEO of Halo Neuroscience, a venture backed start-up based in San Francisco developing neuroscience-based technology that accelerates performance gains for elite athletes. Prior to Halo, Dr. Chao was the Head of Business Development at NeuroPace where he played a central role in the development of the world’s first closed-loop neuromodulation device for the treatment of epilepsy. Dr. Chao was a consultant at McKinsey & Company in their New York office and received his M.D. and M.S. in neuroscience from Stanford University.

Competitive rower Brett Wingeier helped build one of the most ambitious Neurotech companies to aid people with epilepsy. Now he and another NeuroPace alum have created Halo, a neurological device that could give athletes another gear in their workouts.

https://bengreenfieldfitness.com/halosport Last week, I posted to Instagram the "most dangerous piece of workout equipment I own".   A photo posted by Ben Greenfield (@bengreenfieldfitness) on Dec 30, 2016 at 9:28pm PST And no, it was not a mace, or a unicycle, or a parachute or any other risky exercise device. Instead, it was a simple piece of headgear that looks like a nice set of earphones. But within that headgear is embedded one of the devices known to modern exercise science when it comes to doing things like making a hard, voluminous workout feel shockingly simple and short, allowing you to acquire skills like a tennis serve or golf swing at double or triple the speed you'd normally be able to, and enabling you to push much, much harder during a workout than you'd ever be able to do without a little bit of help from modern brain biohacking. The device is called a Halo, and I call it "dangerous" because it allows me to push my body and brain to levels I'd never be able to reach on my own. And it's all based on the science of something called "neuropriming". Developed from fifteen years of academic research, neuropriming is basically the process of causing excitability of motor neurons before or during athletic and exercise training to things like improve strength, skill, explosiveness, and endurance. Michael Johnson, 4x Olympic Gold Medalist says that "...it's doing something that we've never seen before – something the sports market's never seen before..." We're talking explosive force development, increased propulsive force, enhanced skill acquisition, increased rate of force development, and host of other factors influenced by the ability of neuropriming to put the brain's motor cortex in a temporary state of hyper-learning that lasts for about an hour. During this post neuropriming time, feeding your brain quality athletic training repetitions results in this information being more fully incorporated into your brain. Essentially, the headgear I've been using allows me to push far harder than my brain would normally let me and makes practice of a skill far more productive and efficient for the brain. Normally, athletes require literally thousands of reps to create the neurologic changes necessary to perform at the highest level come game time. But this technology changes all that. It's called a "". Dr. Daniel Chao, my guest on today's podcast, is a neurotech entrepreneur who specializes in devices that improve brain performance. He is the co-founder and CEO of . The company's first product, Halo Sport, is the first neurostimulation system built specifically for athletes. Before Halo, Dr. Chao was the head of business development at NeuroPace where he played a central role in the development of the world's first responsive neurostimulation system that was approved by the FDA for the treatment of epilepsy in a unanimous 13-0 vote. Prior to Neuropace, Dr. Chao was a consultant at McKinsey & Company and earned his M.D. and M.S. in neuroscience from Stanford University. During our discussion, you'll discover: -The special part of the brain mammals possess that other less complex species do not, and how you can target that specific area of the brain...[10:40] -How something called transcranial direct current stimulation, also known as tDCS, can be used to stimulate certain section of your brain...[12:52] -What kind of studies have been done on "neuropriming" to actually show whether or not it actually works...[15:10] -Why workouts and skill acquisition actually feel easier after you "shock your brain"...[18:00] -When shocking your brain can actually be safe, and when you should avoid it like the plague...[21:45] -Whether something like this can be used general cognitive performance such as language learning or focus...[27:30 & 30:00] -How to use tDCS stimulation for video gaming and playing instruments...[32:25] -The super-charged sniper training RadioLab episode on which Ben first discovered tDCS and how the Halo is any different than the 20 dollar "make your own TDCS" threads on Reddit...[39:05] -The pro athletes currently using the Halo and what they have reported for results...[45:25] -Whether or not this type of brain training is considered neurodoping by the World Anti Doping Association...[53:20] -What happens if you wear headgear is too far forward or too far back...[59:50] -And much more... Resources from this episode: - - - - - Do you have questions, thoughts or feedback for Kane or me? Leave your comments at  and one of us will reply!

1) School aged cognition in children exposed to levetiracetam, topiramate or sodium valproate2) What's Trending: Interview with David Spencer about his book titled: “Navigating life with epilepsy” 3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. Rebecca Bromley about her paper about school aged cognition in children exposed to levetiracetam, topiramate or sodium valproate. Dr. Ted Burns is interviewing Dr. David Spencer for our “What's Trending” feature of the week about his recently published Neurology Now book titled: “Navigating life with epilepsy.” In the next part of the podcast Dr. Jeff Ratliff interviews Prof. Kailash Bhatia on the topic of “how to approach” dystonia.DISCLOSURES: Dr. Fountain is an epileptologist at the University of Virginia Comprehensive Epilepsy Program (100% effort).Dr. Bromley provided expert testimony regarding fetal valproate syndrome in the UK; although this case did not go to court and received research support from Epilepsy Research UK.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Spencer serves as Patient Page Editor for Neurology®, including past 2 years EMedicine, Chief Editor, Journal of Behavior and Brain Science, Associate Editor Neurology Now, Professional Advisory Board, including past 2 years Epilepsy Currents: Contributing editor; received honorariafrom NeuroPace Inc.; receives research support from NeuroPace, Inc., Upsher-Smith Laboratories, Inc., and Acorda; and was a consultant in a legal case. Prof. Bhatia serves as Co-Editor in Chief for Movement disorders Clinical Practice, serves as an Associate Editor for Movement Disorders, serves as an editorial board member of Therapeutic Advances in Neurological Disorders; received funding for travel from GlaxoSmithKline, Orion Corporation, Ipsen Pharmaceuticals, Inc., Merz Pharmaceuticals, LLC, Sun Pharmaceuticals Ltd, received honoraria from GlaxoSmithKline, Ipsen Pharmaceuticals, Inc., Merz Pharmaceuticals, LLC, Sun Pharmaceutical Industries Ltd.; is a consultant for Allergan, Inc., Ipsen Pharmaceuticals, Inc., MerzPharmaceuticals, LLC; receives royalties from the publication of Oxford Specialist Handbook of Parkinson's Disease and Other Movement Disorders, Marsdens book of Movement disorder, Lancet Neurology review article; receives research support from Wellcome Trust MRC strategic neurodegenerative disease initiative award, Parkinson's UK, Dystonia Coalition and The Bachmann-Strauss Foundation.

1) Neurology® Genetics: Late diagnosis of cerebral folate deficiency: Fewer seizures with folinic acid in adult siblings 2) e-Pearl topic: Stroke-like migraine attacks after radiation therapy (SMART) Syndrome3) Topic of the month: Neurology Today story about unraveling the genetics of Alzheimer disease and attending the ‘Oscars of Science' This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. Dave Dyment about his Neurology: Genetics paper on late diagnosis of cerebral folate deficiency. Dr. Ilena George is reading our e-Pearl of the week about stroke-like migraine attacks after radiation therapy (SMART) syndrome. Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of unraveling the genetics of Alzheimer disease and attending the ‘Oscars of Science.' DISCLOSURES: Dr. Fountain performs clinical procedures as epileptologist (100% effort) at the University of Virginia Comprehensive Epilepsy Program; receives research support from UCB, SK Life Sciences, Inc., Sunovion Pharmaceuticals, Inc., Medtronic, Inc., NeuroPace, Inc. and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. George serves on the editorial team for the Neurology Resident and Fellow Section.Dr. Hardy serves on the scientific advisory boards for Eisai Inc. and Eli Lilly and Company; is a Consultant for Eisai Inc.NO CME WILL BE OFFERED THIS WEEK.

1) Update of quality measures in epilepsy and 2) Topic of the month: Implementation of genetic testing. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Suski interviews Dr. Nathan Fountain about his paper on the update of quality measures in epilepsy. Dr. Sarah Wesley is reading our e-Pearl of the week about hemicrania continua. In the next part of the podcast Dr. Ted Burns interviews Drs. Radhika Dhamija and Christopher Klein about the topic of next generation sequencing. The participants had nothing to disclose except Drs. Fountain, Wesley, Burns and Klein.Dr. Fountain performs clinical procedures as epileptologist (100% effort) at the University of Virginia Comprehensive Epilepsy Program; receives research support from UCB, SK Life Sciences, Inc., Sunovion Pharmaceuticals, Inc., Medtronic, Inc., NeuroPace, Inc. and the NIH.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Klein serves as an editorial board member of Journal of Peripheral Nerve Society; and receives research support from NIH.

1) Utilization of antiepileptic drugs in pregnant women in Florida Medicaid and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. Xuerong Wen about her paper on the utilization of antiepileptic drugs in pregnant women in Florida Medicaid. Dr. James Addington is reading our e-Pearl of the week about primary orthostatic tremor. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Victor Urrutia about the topic of hemoglobinopathies and stroke. The participants had nothing to disclose except Drs. Fountain, Addington, Johansen and Urrutia.Dr. Fountain performs clinical procedures as epileptologist (100% effort) at the University of Virginia Comprehensive Epilepsy Program; receives research support from UCB, SK Life Sciences, Inc., Sunovion Pharmaceuticals, Inc., Medtronic, Inc., NeuroPace, Inc. and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Urrutia serves as a Guest Editor for Frontiers; was asked to consult for New York University to conduct a stroke center certification mock survey; receives research support from Genentech, Inc. and the NIH.

1) Skin nerve a-synuclein deposits being a biomarker for idiopathic Parkinson disease and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Ratliff interviews Dr. Vincenzo Donadio about his paper on skin nerve ?-synuclein deposits being a biomarker for idiopathic Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about cognitive impairment in pediatric multiple sclerosis. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Nathan Fountain about epilepsy therapeutics: Lacosamide. The participants had nothing to disclose except Drs. Fountain and Numis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.

1) Rolandic epilepsy has little effect on adult life 30 years later and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Drs. Carol and Peter Camfield about their paper on how rolandic epilepsy had little effect on adult life 30 years later. Dr. Adam Numis is reading our e-Pearl of the week about lower cranial nerve dysfunction. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Jacqueline French about epilepsy therapeutics: Perampanel. There is different intro music, "Goofy Vocal Groove" by Dave Girtsman in this podcast. The song may be found at http://freemusicarchive.org/music/Dave_Girtsman/Silly_Songs/11_-_dave_girtsman_-_goofy_vocal_groove_kzz01_vbr. The original work was not changed ii any way and is licensed under a Attribution-NonCommercial-ShareAlike 3.0 International License. The participants had nothing to disclose except Drs. Fountain, Peter Camfield, Numis and French.Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.Dr. Peter Camfield serves as an editorial board member of Journal of Child Neurology and Pediatric Neurology Epileptic Disorders Journal.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. French serves as an Associate Editor for Epilepsia; serves as an editorial board member of Lancet Neurology, Neurology Today, Epilepsy Currents; serves on the scientific advisory board for Electrocore, Epilepsy Therapy Project, UCB, Eisai Inc., SK Corporation, Marinus, Upsher-Smith Laboratories, Inc., Sunovion Inc., Vertex Pharmaceuticals, Novartis, Epilepsy Study Consortium; received paid travel to present findings at scientific meetings, present at investigators meetings attend advisory boards or give lectures from Acorda, UCB, Eisai, Inc., Johnson and Johnson, Upsher-Smith Laboratories, Inc., Novartis, Pfizer Inc, Eli Lilly and Company, LCGH, Vertex Pharmaceuticals, Supernus, Marinus Pharmaceuticals, Inc., SK Corporation; receives research support from Eisai, Inc., UCB, SK Corporation, Valeant Pharmaceuticals International, Upsher-Smith Laboratories, Inc., Vertex Pharmaceuticals, Pfizer Inc, Marinus Pharmaceuticals, Brain Sentinal, Epilepsy Research Foundation, The Milken Foundation, The Epilepsy Study Consortium and the NIH.

This episode of Epilepsy.com Reports includes an exclusive interview with Frank Fischer, the CEO of Neuropace, talking about the newly approved Responsive Neurostimulation System (RNS). Learn more about the RNS

1) Patients treated with antiepileptic drugs and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. John Wark and Prof. Terry O' Brien about their paper on falls and fractures in patients treated with antiepileptic drugs. Dr. Jennifer Fugate is reading our e-Pearl of the week about Duchenne muscular dystrophy. In the next part of the podcast Dr. Alberto Espay continues his interview with Drs. Titulaer and Vincent about their lecture on clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Next week, we will continue with interviews from other plenary sessions. All participants have disclosures.Dr. Fountain serves as an editorial board member of Epilepsy Currents, serves on the Board of Directors, National Association of Epilepsy Centers, receives travel reimbursement from UCB; performs EEG interpretation for the University of Virginia (10% effort); receives research support from UCB, Sepracor Inc., Medtronic, Inc., Vertex Pharmaceuticals and NeuroPace; and is funded by the NIH.Dr. Wark serves on the scientific advisory boards for Amgen/GlaxoSmithKline, Novartis and LactoPharma; serves as a specialist editor of Clinical Science; editorial board members of Osteoporosis International and Journal of Osteoporosis; serves on the speakers' bureau of Servier, Amgen, Novartis, Sanofi-aventis, Eli Lilly and Company, Merck Serono, Sharp Dohme Company; serves on the speakers' bureau of Servier, Amgen, Novartis, Amgen, Novartis, Sanofi-aventis, Eli Lilly and Company, Merck Serono, Sharp Dohme Company; received travel reimbursement from Servier; is a consultant for Vactec and AstraZeneca; performs bone density testing for the Royal Melbourne Hospital (10% effort); receives royalties from the publication of the book Physical Activity and Bone Health; receives research support from Novartis, UCB, Sanofi-aventis, Eli Lilly and Company, Monash University, LaTrobe University, National Health and Medical Research Council of Australia, Victorian Cancer Agency and ANZ Trustees.Prof. O'Brien served as editorial board members of Epilepsia, Journal of Clinical Neuroscience and Epilepsy and Behavior; serves on the speakers' bureaus of UCB, Sanofi-aventis and SiGen and receives research support from UCB, Sanofi-aventis Jansen-Cilag, Royal Melbourne Hospital Neuroscience Foundation and Epilepsy Research Foundation and is funded by the NIH and NHMRC.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Titulaer received research support from a KWF fellowship of the Dutch Cancer Society.Dr. Vincent served on the scientific advisory board for Patrick Berthoud Trust as Chair and member of the MGFA SAB; received honoraria from Baxter International; serves as Associate Editor for Brain; is a consultant for Athena Diagnostics; receives royalties from the publications of Clinical Neuroimmunology Blackwells Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press; receives revenue from Athena Diagnostics and RSR Ltd for MuSK antibodies for a patent, holds a patent for CASPR2, Lgi1, Contactin2 antibodies; receives research support from NIH, EU network grant, Euroimmun AG and Sir Halley Stewart Trust; performs neuroimmunology service for her department and is associated with Myasthenia Gravis Foundation of America.

1) Folic acid supplementation and 2) Topic of the month: Historical interviews. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Drs. Sheffali Gulati and Ravindra Arya about their paper on folic acid supplementation. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about the 'hot and dry foot' as a sign of cancer. In the next part of the podcast Dr. Farrah Mateen interviews Dr. C. Miller Fisher as we continue our month of historical interviews. The participants had nothing to disclose except Drs. Fountain, Gulati, Clardy and Mateen.Dr. Fountain serves on the Scientific Advisory Board and has received funding for travel from UCB; serves on the editorial board of Epilepsy Currents; estimates that 10% of his clinical effort at the University of Virginia EEG Lab is spent on EEG interpretation; receives research support from UCB, Vertex Pharmaceuticals, Sepracor Inc., Medtronic, Inc., NeuroPace, Inc., and the NIH (R01 NS 058634- 01A2m [Site PI] and U01 NS 053998 [Site PI],Dr. Gulati serves on the editorial board of the Indian Journal of Pediatrics; and receives research support from the NIH, Autism Speaks, and National Trust.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Mateen served on the editorial team for the Neurology® Resident and Fellow Section and is supported by the 2010 Practice Research Grant from the American Academy of Neurology.

In this week's episode of Epilepsy.com's Hallway Conversations, Dr. Joseph Sirven, Professor of Neurology at Mayo Clinic Arizona and Editor-in-Chief of Epilepsy.com/Professionals, interviews Dr. Martha Morrell, Chief Science Officer of Neuropace, Inc. The topic will be Responsive Neurostimulation System: Preliminary Results. This is a live taping with no questions to be answered live.

This Podcast for the Neurology Journal begins with Dr. John H. Noseworthy, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Drs. James Kiely and Christopher Wright interview Dr. Kimford Meador about his paper on pregnancy registries in epilepsy. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week. The podcast concludes with Dr. Chris Boes interviewing Dr. William Landau about his historical papers on Landau-Kleffner syndrome for the Lesson of the Week segment. The participants had nothing to disclose except for Dr. Meador. Dr. Meador disclosures are: Research Support (>$10K): NIH, Eisai, GlaxoSmithKline, Marius, McKnight Brain Institute, Myriad, Neuropace, Pharma, SAM Technology, UCB;